Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Applied DNA Sciences ( (BNBX) ) is now available.
On December 12, 2025, Applied DNA Sciences held a special meeting of stockholders where several key proposals were approved. These included the exercisability of certain pre-funded warrants and common stock purchase warrants, an amendment to increase the number of authorized shares of Common Stock from 200,000,000 to 500,000,000, and an amendment to the 2020 Equity Incentive Plan to increase the number of authorized shares reserved for issuance by 5,000,000 shares. These approvals are expected to impact the company’s operations by potentially expanding its capital structure and enhancing its equity incentive offerings.
Spark’s Take on BNBX Stock
According to Spark, TipRanks’ AI Analyst, BNBX is a Neutral.
Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.
To see Spark’s full report on BNBX stock, click here.
More about Applied DNA Sciences
Average Trading Volume: 1,286,494
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.99M
For detailed information about BNBX stock, go to TipRanks’ Stock Analysis page.